182 related articles for article (PubMed ID: 38750051)
1. Structure and genome editing of type I-B CRISPR-Cas.
Lu M; Yu C; Zhang Y; Ju W; Ye Z; Hua C; Mao J; Hu C; Yang Z; Xiao Y
Nat Commun; 2024 May; 15(1):4126. PubMed ID: 38750051
[TBL] [Abstract][Full Text] [Related]
2. Allosteric control of type I-A CRISPR-Cas3 complexes and establishment as effective nucleic acid detection and human genome editing tools.
Hu C; Ni D; Nam KH; Majumdar S; McLean J; Stahlberg H; Terns MP; Ke A
Mol Cell; 2022 Aug; 82(15):2754-2768.e5. PubMed ID: 35835111
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for assembly of non-canonical small subunits into type I-C Cascade.
O'Brien RE; Santos IC; Wrapp D; Bravo JPK; Schwartz EA; Brodbelt JS; Taylor DW
Nat Commun; 2020 Nov; 11(1):5931. PubMed ID: 33230133
[TBL] [Abstract][Full Text] [Related]
4. Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems.
Tan R; Krueger RK; Gramelspacher MJ; Zhou X; Xiao Y; Ke A; Hou Z; Zhang Y
Mol Cell; 2022 Feb; 82(4):852-867.e5. PubMed ID: 35051351
[TBL] [Abstract][Full Text] [Related]
5. Genome editing in mammalian cells using the CRISPR type I-D nuclease.
Osakabe K; Wada N; Murakami E; Miyashita N; Osakabe Y
Nucleic Acids Res; 2021 Jun; 49(11):6347-6363. PubMed ID: 34076237
[TBL] [Abstract][Full Text] [Related]
6. Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.
Hu C; Myers MT; Zhou X; Hou Z; Lozen ML; Nam KH; Zhang Y; Ke A
Mol Cell; 2024 Feb; 84(3):463-475.e5. PubMed ID: 38242128
[TBL] [Abstract][Full Text] [Related]
7. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
[TBL] [Abstract][Full Text] [Related]
8. DNA interference is controlled by R-loop length in a type I-F1 CRISPR-Cas system.
Tuminauskaite D; Norkunaite D; Fiodorovaite M; Tumas S; Songailiene I; Tamulaitiene G; Sinkunas T
BMC Biol; 2020 Jun; 18(1):65. PubMed ID: 32539804
[TBL] [Abstract][Full Text] [Related]
9. Structure Basis for Directional R-loop Formation and Substrate Handover Mechanisms in Type I CRISPR-Cas System.
Xiao Y; Luo M; Hayes RP; Kim J; Ng S; Ding F; Liao M; Ke A
Cell; 2017 Jun; 170(1):48-60.e11. PubMed ID: 28666122
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3.
Gong B; Shin M; Sun J; Jung CH; Bolt EL; van der Oost J; Kim JS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16359-64. PubMed ID: 25368186
[TBL] [Abstract][Full Text] [Related]
11. Structure basis for RNA-guided DNA degradation by Cascade and Cas3.
Xiao Y; Luo M; Dolan AE; Liao M; Ke A
Science; 2018 Jul; 361(6397):. PubMed ID: 29880725
[TBL] [Abstract][Full Text] [Related]
12. Introducing a Spectrum of Long-Range Genomic Deletions in Human Embryonic Stem Cells Using Type I CRISPR-Cas.
Dolan AE; Hou Z; Xiao Y; Gramelspacher MJ; Heo J; Howden SE; Freddolino PL; Ke A; Zhang Y
Mol Cell; 2019 Jun; 74(5):936-950.e5. PubMed ID: 30975459
[TBL] [Abstract][Full Text] [Related]
13. CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-guided interference.
Hochstrasser ML; Taylor DW; Bhat P; Guegler CK; Sternberg SH; Nogales E; Doudna JA
Proc Natl Acad Sci U S A; 2014 May; 111(18):6618-23. PubMed ID: 24748111
[TBL] [Abstract][Full Text] [Related]
14. Harnessing type I CRISPR-Cas systems for genome engineering in human cells.
Cameron P; Coons MM; Klompe SE; Lied AM; Smith SC; Vidal B; Donohoue PD; Rotstein T; Kohrs BW; Nyer DB; Kennedy R; Banh LM; Williams C; Toh MS; Irby MJ; Edwards LS; Lin CH; Owen ALG; Künne T; van der Oost J; Brouns SJJ; Slorach EM; Fuller CK; Gradia S; Kanner SB; May AP; Sternberg SH
Nat Biotechnol; 2019 Dec; 37(12):1471-1477. PubMed ID: 31740839
[TBL] [Abstract][Full Text] [Related]
15. Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.
Hou Z; Hu C; Ke A; Zhang Y
Curr Protoc; 2022 Feb; 2(2):e361. PubMed ID: 35129865
[TBL] [
